MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--
Medgenics, Inc. (NYSE MKT:MDGN and AIM:MEDU, MEDG) (the
“Company”), the developer of a novel technology for the sustained
production and delivery of therapeutic proteins in patients using their
own tissue, announces the appointment of Wilbur H. (Bill) Gantz to the
Company’s Board of Directors effective October 16, 2013. With this
appointment, the size of the Medgenics board increases to 10 directors.
Mr. Gantz is President of PathoCapital, an investor in healthcare
companies. He previously served as Executive Chairman and Chief
Executive Officer of Ovation Pharmaceuticals, Inc., which was sold to
Lundbeck, AG in 2009, and as Chairman, Chief Executive Officer and
President of PathoGenesis Corporation, a biopharmaceutical company that
was sold to Chiron, Inc. in 2000. Prior to founding PathoGenesis, from
1987 to 1992 he served as President of Baxter International, Inc., a
manufacturer and marketer of healthcare products. He joined Baxter in
1966 and held various management positions, including Vice President,
Europe and President, International Division, prior to being named
Executive Vice President and Chief Operating Officer in 1980.
“Bill is a prominent and highly regarded figure in the biopharmaceutical
industry, and we are delighted to welcome him to our Board of Directors.
He has demonstrated leadership at both global pharmaceutical companies
as well as at a series of entrepreneurial biotechnology companies that
he built and guided to success," said Mike Cola, President and Chief
Executive Officer of Medgenics. “Bill’s insights will be instrumental in
guiding Medgenics as we advance our clinical development programs and
build a successful biotechnology company."
“I am delighted to be joining Medgenics at this important juncture in
its clinical development,” said Mr. Gantz. “The Company’s novel,
technology platform holds great potential to change the paradigm for
therapeutic proteins across a number of chronic conditions. I look
forward to working with the Medgenics team and my fellow directors to
advance the development of this promising platform technology.”
Mr. Gantz is currently Executive Chairman, Naurex, Inc., a biotechnology
company developing central nervous system therapeutics. He is a Vice
Chairman of the Board of Trustees and Chair of the Committee on Science
of the Field Museum of Natural History in Chicago. He is the former
Chairman of the Board of Harris Financial Corporation and a former
director of the Gillette Company, W.W. Grainger, Inc., Gambio, Inc. and
Baxter International. He is a past trustee of Princeton University. Mr
Gantz is 75 years old. In addition to the above, is a partner of Adam
Street Partners, LLP and a director of Neurowave, Inc.